Fisher Asset Management LLC Purchases 253,808 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fisher Asset Management LLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 210.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 374,352 shares of the biopharmaceutical company’s stock after acquiring an additional 253,808 shares during the quarter. Fisher Asset Management LLC owned approximately 0.56% of Celldex Therapeutics worth $12,724,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Novo Holdings A S bought a new position in shares of Celldex Therapeutics in the 2nd quarter worth approximately $31,458,000. Point72 Asset Management L.P. grew its position in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after buying an additional 654,194 shares during the period. Vanguard Group Inc. increased its holdings in Celldex Therapeutics by 19.8% during the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after buying an additional 604,251 shares during the last quarter. Marshall Wace LLP raised its position in Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after acquiring an additional 479,068 shares during the period. Finally, Jennison Associates LLC boosted its stake in shares of Celldex Therapeutics by 32.0% during the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CLDX. Citigroup assumed coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price on the stock. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a research note on Monday, September 30th. They set a “neutral” rating and a $45.00 price objective for the company. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Insider Buying and Selling at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 3.80% of the company’s stock.

Celldex Therapeutics Stock Performance

CLDX opened at $27.89 on Thursday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -10.85 and a beta of 1.60. The company has a fifty day moving average of $29.35 and a 200 day moving average of $34.60. Celldex Therapeutics, Inc. has a fifty-two week low of $22.93 and a fifty-two week high of $53.18.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.